What type of study is this?

August 25, 2025Open Access

Figure 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

Key Points

HER2 expression varies in metastatic prostate and urothelial cancers, indicating distinct treatment approaches may be necessary.
The analysis included autopsy specimens showing diverse HER2 IHC scores across tumors in both cancer types.
Immunohistochemistry was used to assess HER2 expression levels in tumor samples, highlighting differences in expression.
These findings suggest that HER2-targeted therapies may be beneficial, but require further validation in clinical settings.

Abstract

A and B, Representative micrographs of HER2 IHC staining in prostate cancer (A) and urothelial cancer (B) autopsy specimens. C, Number of patients with at least one tumor with the indicated HER2 IHC score, color coded by cancer type. D, Number of tumors across all patients with the indicated HER2 IHC score, color coded by cancer type. E and F, Percent of tumors expressing the indicated level of HER2 staining by IHC according to the tumor site sampled in prostate (E) and urothelial (F) cancer cohorts. Anatomic sites with only one representative tumor were excluded. PC, prostate cancer; UC, urothelial carcinoma.

Ask AI

Helpful

Bookmark

View Full Paper